1. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model
- Author
-
O'Geen, Henriette, Beitnere, Ulrika, Garcia, Miranda S, Adhikari, Anna, Cameron, David L, Fenton, Timothy A, Copping, Nycole A, Deng, Peter, Lock, Samantha, Halmai, Julian ANM, Villegas, Isaac J, Liu, Jiajian, Wang, Danhui, Fink, Kyle D, Silverman, Jill L, and Segal, David J
- Subjects
Medical Biotechnology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Gene Therapy ,Biotechnology ,Intellectual and Developmental Disabilities (IDD) ,Pediatric ,Brain Disorders ,Genetics ,Behavioral and Social Science ,Rare Diseases ,Orphan Drug ,Neurosciences ,Development of treatments and therapeutic interventions ,5.2 Cellular and gene therapies ,Neurological ,Animals ,Mice ,Angelman Syndrome ,Brain ,Gene Expression Regulation ,Transcription Factors ,Phenotype ,Ubiquitin-Protein Ligases ,AAV therapy ,AS ,ATF ,Angelman syndrome ,UBE3A ,artificial transcription factor ,brain-wide delivery ,epigenome editing ,imprinting ,zinc finger ,Biological Sciences ,Technology ,Medical and Health Sciences ,Clinical sciences ,Medical biotechnology - Abstract
Angelman syndrome (AS) is a neurogenetic disorder caused by the loss of ubiquitin ligase E3A (UBE3A) gene expression in the brain. The UBE3A gene is paternally imprinted in brain neurons. Clinical features of AS are primarily due to the loss of maternally expressed UBE3A in the brain. A healthy copy of paternal UBE3A is present in the brain but is silenced by a long non-coding antisense transcript (UBE3A-ATS). Here, we demonstrate that an artificial transcription factor (ATF-S1K) can silence Ube3a-ATS in an adult mouse model of Angelman syndrome (AS) and restore endogenous physiological expression of paternal Ube3a. A single injection of adeno-associated virus (AAV) expressing ATF-S1K (AAV-S1K) into the tail vein enabled whole-brain transduction and restored UBE3A protein in neurons to ∼25% of wild-type protein. The ATF-S1K treatment was highly specific to the target site with no detectable inflammatory response 5 weeks after AAV-S1K administration. AAV-S1K treatment of AS mice showed behavioral rescue in exploratory locomotion, a task involving gross and fine motor abilities, similar to low ambulation and velocity in AS patients. The specificity and tolerability of a single injection of AAV-S1K therapy for AS demonstrate the use of ATFs as a promising translational approach for AS.
- Published
- 2023